Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company engaged in treating neuroinflammation with a current focus on CNS disorders and rare diseases. The company is headquartered in Palm Beach Gardens, Florida and currently employs 4 full-time employees. The company went IPO on 2024-12-03. The firm has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The firm has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. The company has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
Follow-Up Questions
Jupiter Neurosciences Inc 'in CEO'su kimdir?
Mr. Christer Rosen 2016 'den beri şirketle birlikte olan Jupiter Neurosciences Inc 'in Chairman of the Board 'ıdır.
JUNS hissesinin fiyat performansı nasıl?
JUNS 'in mevcut fiyatı $1.46 'dir, son işlem günde 2.09% increased etti.
Jupiter Neurosciences Inc için ana iş temaları veya sektörler nelerdir?
Jupiter Neurosciences Inc Pharmaceuticals endüstrisine ait ve sektör Health Care 'dir
Wall Street analistlerine göre, 3 analist Jupiter Neurosciences Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 2 güçlü al, 4 al, 1 tut, 0 sat ve 2 güçlü sat içermektedir
